Asarina Pharma shows efficacy of Sepranolone in Tourette’s syndrome on par with current first line treatment, but without side effects
Stockholm, April 2, 2019: Sepranolone reduces tics in an animal model of Tourette’s syndrome on par with Haldol, without inducing any motor side effects.The research group led by Prof. Marco Bortolato at the University of Utah has found that Sepranolone reduces the number of tic-like responses in the D1CT-7 mouse model of Tourette´s syndrome (TS), with an efficacy comparable to the benchmark therapy haloperidol (Haldol). While Asarina Pharma’s main focus is on clinical development of Sepranolone for Premenstrual Dysphoric Disorder (PMDD) and Menstrual Migraine (MM), the company is